{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:16:51Z","timestamp":1794863811241,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Gastric cancer (GC) is characterised by a dense stromal microenvironment, lack of therapeutic targets, and limited effective treatment options, collectively leading to a poor prognosis. Here, we identify UL16 binding protein 2 (ULBP2) as a potential therapeutic target in GC. Mechanistically, ULBP2 overexpression activates the TGF-\u03b2 signalling pathway, promoting the activation of cancer-associated fibroblasts (CAFs) and tumor progression in GC. Furthermore, we developed ULBP2 CAR-T cells and assessed their therapeutic potential in GC cell lines, organoids, cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models. We showed that ULBP2 CAR-T cells effectively eliminated GC cell lines and organoids and, either alone or in combination with an anti-PD-1 antibody, significantly inhibited tumor growth and prolonged survival in both CDX and PDX mouse models. In conclusion, ULBP2 contributes to GC progression by promoting TGF-\u03b2 mediated CAF activation, which collectively reinforce the dense stromal microenvironment. Targeting ULBP2 suppresses tumor growth, reduces stromal deposition, and promotes T cell infiltration, thereby enhancing the efficacy of immunotherapy in GC.<\/jats:p>","DOI":"10.1038\/s41419-025-07905-5","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T23:00:27Z","timestamp":1754607627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6803-2331","authenticated-orcid":false,"given":"Wentao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huinian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-7176","authenticated-orcid":false,"given":"Long","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-0905","authenticated-orcid":false,"given":"Zuoyi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"7905_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7905_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"7905_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","volume":"24","author":"L Arpinati","year":"2024","unstructured":"Arpinati L, Carradori G, Scherz-Shouval R. CAF-induced physical constraints controlling T cell state and localization in solid tumors. Nat Rev Cancer. 2024;24:676\u201393.","journal-title":"Nat Rev Cancer"},{"key":"7905_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"7905_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10:627\u201342.","journal-title":"Trends Cancer"},{"key":"7905_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"7905_CR7","first-page":"275","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73:275\u201385.","journal-title":"CA Cancer J Clin"},{"key":"7905_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumors: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"7905_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, Chong X, Zhou T, Ma M, Gong J, Zhang M, et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study. Chin J Cancer Res. 2024;36:78\u201389.","journal-title":"Chin J Cancer Res"},{"key":"7905_CR10","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30:2224\u201334.","journal-title":"Nat Med"},{"key":"7905_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn3774","volume":"8","author":"L Qin","year":"2022","unstructured":"Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, et al. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv. 2022;8:eabn3774.","journal-title":"Sci Adv"},{"key":"7905_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","volume":"9","author":"Y Song","year":"2018","unstructured":"Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9:867\u201378.","journal-title":"Protein Cell"},{"key":"7905_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","volume":"12","author":"J Lv","year":"2019","unstructured":"Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12:18.","journal-title":"J Hematol Oncol"},{"key":"7905_CR14","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00262-021-02891-x","volume":"70","author":"Y Han","year":"2021","unstructured":"Han Y, Sun B, Cai H, Xuan Y. Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy. Cancer Immunol Immunother. 2021;70:2795\u2013803.","journal-title":"Cancer Immunol Immunother"},{"key":"7905_CR15","first-page":"1846","volume":"9","author":"W Zhao","year":"2019","unstructured":"Zhao W, Jia L, Zhang M, Huang X, Qian P, Tang Q, et al. The killing effect of novel bi-specific Trop2\/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9:1846\u201356.","journal-title":"Am J Cancer Res"},{"key":"7905_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18:29.","journal-title":"Mol Cancer"},{"key":"7905_CR17","doi-asserted-by":"crossref","unstructured":"Ding H, Yang X, Wei Y. Fusion proteins of NKG2D\/NKG2DL in cancer immunotherapy. Int J Mol Sci. 2018;19:177.","DOI":"10.3390\/ijms19010177"},{"key":"7905_CR18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","volume":"7","author":"B Sun","year":"2019","unstructured":"Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 2019;7:1813\u201323.","journal-title":"Cancer Immunol Res"},{"key":"7905_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","volume":"7","author":"D Yang","year":"2019","unstructured":"Yang D, Sun B, Dai H, Li W, Shi L, Zhang P, et al. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019;7:171.","journal-title":"J Immunother Cancer"},{"key":"7905_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","volume":"11","author":"Y Han","year":"2018","unstructured":"Han Y, Xie W, Song DG, Powell DJ Jr. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11:92.","journal-title":"J Hematol Oncol"},{"key":"7905_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-018-3670-0","volume":"82","author":"K Tao","year":"2018","unstructured":"Tao K, He M, Tao F, Xu G, Ye M, Zheng Y, et al. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharm. 2018;82:815\u201327.","journal-title":"Cancer Chemother Pharm"},{"key":"7905_CR22","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1111\/cas.15828","volume":"114","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liang K, Zhou X, Zhang X, Xu H, Dai H, et al. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer. Cancer Sci. 2023;114:2798\u2013809.","journal-title":"Cancer Sci"},{"key":"7905_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbrc.2019.07.020","volume":"517","author":"T Kegasawa","year":"2019","unstructured":"Kegasawa T, Tatsumi T, Yoshioka T, Suda T, Ikezawa K, Nakabori T, et al. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. Biochem Biophys Res Commun. 2019;517:84\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"7905_CR24","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s11010-022-04647-2","volume":"478","author":"X Yang","year":"2023","unstructured":"Yang X, Su X, Wang Z, Yu Y, Wu Z, Zhang D. ULBP2 is a biomarker related to prognosis and immunity in colon cancer. Mol Cell Biochem. 2023;478:2207\u201319.","journal-title":"Mol Cell Biochem"},{"key":"7905_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23687","volume":"10","author":"R Feng","year":"2024","unstructured":"Feng R, Xu J, Huang J, Liu J, Wang X, Wang J, et al. An immune-related prognostic gene ULBP2 is correlated with immunosuppressive tumor microenvironment and immunotherapy in breast cancer. Heliyon. 2024;10:e23687.","journal-title":"Heliyon"},{"key":"7905_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104.","journal-title":"Mol Cancer"},{"key":"7905_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcancer.2013.12.008","volume":"25","author":"A Calon","year":"2014","unstructured":"Calon A, Tauriello DV, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol. 2014;25:15\u201322.","journal-title":"Semin Cancer Biol"},{"key":"7905_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-019-1897-5","volume":"577","author":"J Su","year":"2020","unstructured":"Su J, Morgani SM, David CJ, Wang Q, Er EE, Huang YH, et al. TGF-beta orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature. 2020;577:566\u201371.","journal-title":"Nature"},{"key":"7905_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","volume":"38","author":"J Si","year":"2020","unstructured":"Si J, Shi X, Sun S, Zou B, Li Y, An D, et al. Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell. 2020;38:551\u201366.e11.","journal-title":"Cancer Cell"},{"key":"7905_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998\u20131013.","journal-title":"Cancer Discov"},{"key":"7905_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/CJI.0000000000000413","volume":"45","author":"A Michaux","year":"2022","unstructured":"Michaux A, Mauen S, Breman E, Dheur MS, Twyffels L, Saerens L, et al. Clinical grade manufacture of CYAD-101, a NKG2D-based, first in class, non-gene-edited allogeneic CAR T-cell therapy. J Immunother. 2022;45:150\u201361.","journal-title":"J Immunother"},{"key":"7905_CR32","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poire X, Lewalle P, Wang ES, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10:e191\u2013e202.","journal-title":"Lancet Haematol"},{"key":"7905_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024;17:65.","journal-title":"J Hematol Oncol"},{"key":"7905_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-24","volume":"12","author":"EM de Kruijf","year":"2012","unstructured":"de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012;12:24.","journal-title":"BMC Cancer"},{"key":"7905_CR35","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/ijc.25156","volume":"127","author":"RW McGilvray","year":"2010","unstructured":"McGilvray RW, Eagle RA, Rolland P, Jafferji I, Trowsdale J, Durrant LG. ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients. Int J Cancer. 2010;127:1412\u201320.","journal-title":"Int J Cancer"},{"key":"7905_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-008-0585-3","volume":"58","author":"K Li","year":"2009","unstructured":"Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, et al. Clinical significance of the NKG2D ligands, MICA\/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58:641\u201352.","journal-title":"Cancer Immunol Immunother"},{"key":"7905_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1242\/jcs.076042","volume":"124","author":"L Fernandez-Messina","year":"2011","unstructured":"Fernandez-Messina L, Ashiru O, Aguera-Gonzalez S, Reyburn HT, Vales-Gomez M. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J Cell Sci. 2011;124:321\u20137.","journal-title":"J Cell Sci"},{"key":"7905_CR38","doi-asserted-by":"publisher","first-page":"e91133","DOI":"10.1371\/journal.pone.0091133","volume":"9","author":"R Wang","year":"2014","unstructured":"Wang R, Sun PD. Natural killer cell-mediated shedding of ULBP2. PLoS One. 2014;9:e91133.","journal-title":"PLoS One"},{"key":"7905_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-262","volume":"11","author":"YP Peng","year":"2013","unstructured":"Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med. 2013;11:262.","journal-title":"J Transl Med"},{"key":"7905_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cellimm.2006.03.002","volume":"239","author":"H Song","year":"2006","unstructured":"Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006;239:22\u201330.","journal-title":"Cell Immunol"},{"key":"7905_CR41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734\u20138.","journal-title":"Nature"},{"key":"7905_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12865-021-00434-8","volume":"22","author":"YS Lee","year":"2021","unstructured":"Lee YS, Choi H, Cho HR, Son WC, Park YS, Kang CD, et al. Downregulation of NKG2DLs by TGF-beta in human lung cancer cells. BMC Immunol. 2021;22:44.","journal-title":"BMC Immunol"},{"key":"7905_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/030089161109700316","volume":"97","author":"JC Lee","year":"2011","unstructured":"Lee JC, Lee KM, Ahn YO, Suh B, Heo DS. A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1. Tumori. 2011;97:350\u20137.","journal-title":"Tumori"},{"key":"7905_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101827","volume":"5","author":"J Obajdin","year":"2024","unstructured":"Obajdin J, Larcombe-Young D, Glover M, Kausar F, Hull CM, Flaherty KR, et al. Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell Rep Med. 2024;5:101827.","journal-title":"Cell Rep Med"},{"key":"7905_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7:363\u201375.","journal-title":"Cancer Immunol Res"},{"key":"7905_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res. 2019;7:100\u201312.","journal-title":"Cancer Immunol Res"},{"key":"7905_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang D, Sun B, Li S, Wei W, Liu X, Cui X, et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med. 2023;15:eadd1951.","journal-title":"Sci Transl Med"},{"key":"7905_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-0716-3858-3_12","volume":"2806","author":"LK Philp","year":"2024","unstructured":"Philp LK. Patient-derived xenograft models for translational prostate cancer research and drug development. Methods Mol Biol. 2024;2806:153\u201385.","journal-title":"Methods Mol Biol"},{"key":"7905_CR49","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173:515\u201328.e17.","journal-title":"Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07905-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:05:56Z","timestamp":1757361956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07905-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7905"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07905-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LQ, WR, JJ, WZ, SG, and HH are inventors on 2 patent applications related to this work, filed by the Lanzhou University Second Hospital and Gansu Yimin Biotechnologies (no. 202410453832.2 and no. 202411739635.3). The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Second Hospital and Clinical Medical School of Lanzhou University.All animal experiments were approved by the Laboratory Animal Ethics Committee ofthe Second Hospital and Clinical Medical School of Lanzhou University (Approval No. D2024-169). All specimens were collected from patients following protocolsapproved by the Human Research Ethics Committee of the Second Hospital andClinical Medical School of Lanzhou University (Approval No. 2024A-163), and writteninformed consent was obtained from all participants. All methods were performed inaccordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"597"}}